India, July 8 -- Chandigarh, July 8, 2025 — Nectar Lifesciences Limited (NSE: NECLIFE, BSE: 532649), a prominent player in the Indian pharmaceutical industry, has announced the signing of a definitive Business Transfer Agreement (BTA) to divest its core business division—including the manufacturing, distribution, and marketing of active pharmaceutical ingredients (APIs) and formulations—to Ceph Lifesciences Private Limited. The deal is valued at ?1,270 crore and will be executed on a slump sale basis.
In a parallel development, Nectar Lifesciences has also entered into an Asset Purchase Agreement (APA) to sell its menthol business assets to Ceph Lifesciences for ?20 crore. These moves mark a strategic restructuring initia...